/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

G

Gilberto de Castro

University of Central Florida(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

475

Papers

33.9K

Citations

52

h-index

144

i10-index

Gilberto de Castro is an academic researcher from University of Central Florida. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Head and Neck Cancer Studies. The author has an h-index of 52, co-authored 404 publications.

ORCID: 0000-0001-8765-3044

Research Topics

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Head and Neck Cancer Studies Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

Papers by this author

works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2015 · The Lancet · 6,440 citations

https://doi.org/10.1016/s0140-6736(15)01281-7

Roy S. Herbst Paul Baas Dong‐Wan Kim Enriqueta Felip

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · The Lancet · 3,270 citations

https://doi.org/10.1016/s0140-6736(18)32409-7

Tony Mok Yi‐Long Wu Iveta Kudaba Dariusz M. Kowalski

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · The Lancet · 3,270 citations

https://doi.org/10.1016/s0140-6736(18)32409-7

Tony Mok Yi‐Long Wu Iveta Kudaba Dariusz M. Kowalski

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2017 · The Lancet · 1,014 citations

https://doi.org/10.1016/s0140-6736(16)32616-2

David Cameron Martine Piccart Richard D. Gelber Marion Procter

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

2007 · British Journal of Cancer · 954 citations

https://doi.org/10.1038/sj.bjc.6603756

Evandro de Azambuja Fátima Cardoso Gilberto de Castro Maria Antonietta Colozza

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

2022 · Journal of Clinical Oncology · 450 citations

https://doi.org/10.1200/jco.21.02508

Kevin J. Harrington Barbara Burtness Richard Greil Denis Soulières

Research topics

topics

Cancer Immunotherapy and Biomarkers

Lung Cancer Treatments and Mutations

Head and Neck Cancer Studies

Lung Cancer Research Studies

Lung Cancer Diagnosis and Treatment

Chat about Author

Papers

Chat

Click to start Chat